QURE
uniQure N.V.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.96
P/S
65.67
EV/EBITDA
-10.63
DCF Value
$-8.06
FCF Yield
-16.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.1%
Operating Margin
-1157.9%
Net Margin
-1236.0%
ROE
-174.0%
ROA
-27.4%
ROIC
-24.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $5.6M | $-37.1M | $-0.59 |
| FY 2025 | $16.1M | $-199.0M | $-3.46 |
| Q3 2025 | $3.7M | $-80.5M | $-1.38 |
| Q2 2025 | $5.3M | $-37.7M | $-0.69 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
NL
Exchange
NASDAQ
Beta
0.75
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.